Shanghai Henlius Biotech (Henlius) and Organon have announced the US Food and Drug Administration (FDA) acceptance of the biologic license application (BLA) for HLX14, a biosimilar candidate of PROLIA/XGEVA (denosumab).
The acquisition would improve Seattle Genetics' late-stage clinical pipeline with Tucatinib, an orally available and highly selective tyrosine kinase inhibitor (TKI) for patients with HER2-positive metastatic breast cancer As per the terms
TAK-426 is a purified, inactivated, alum-adjuvanted and whole Zika virus vaccine candidate. Zika holds capacity to induce congenital Zika syndrome (CZS), including microcephaly and other congenital brain abnormalities,
The Phase I/II study (STELLAR-001) will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with Innate's investigational first-in-class anti-C5aR monoclonal antibody, IPH5401,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
